教育经历

1986-1990 美国迈阿密大学，微生物与免疫学， 博士

1978-1983 上海医科大学，临床医学，学士

工作经历

2021年全职回清华大学任教，现任清华大学医学院讲席教授

2015-2021年任德州大学西南医学中心病理系冠名教授

1998-2015年在University of Chicago任职病理学系教授，主治医生

1994-1998年 在Washington University School of Medicine担任住院医生

1991-1993年在National Jewish Center for Immunology and Respiratory Medicine, Denver从事博士后研究

研究简介

率先提出肿瘤放射治疗诱导免疫应答理论，揭示细胞内STING信号和免疫细胞间互作机制。

揭示肿瘤受体信号阻断而诱导的应激信号，从而触发先天免疫和适应性免疫，使肿瘤消退。

首创细胞因子前药设计，用于多种实体肿瘤的治疗。

傅阳心教授在临床和基础医学研究领域都具有重大创新，现已在Science，Nature，Nature Medicine等领域内顶尖学术刊物发表260多篇高水平的学术研究论文，文章被引用次数超过45000余次，H-index 111，入选高被引科学家，成为少数同时在医学和基础科研领域都取得突出成绩的医生和科学家。他在肿瘤免疫学领域内尤其具有很高的声望和影响力，是药物、放疗和靶向治疗对免疫细胞及分子机制研究的开拓者。

主要荣誉

曾获Howard Hughes Medical Institute Fellowship for Physician Scientist及 NIH Clinical Investigator Award等奖。

代表性成果

1.Ren Z, Zhang A, Sun Z, Liang Y, Ye J, Qiao J, Li B, Fu YX. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. J Clin Invest. 2022 Feb 1;132(3):e153604.

2. Xue D, Moon B, Liao J, Guo J, Zou Z, Han Y, Cao S, Wang Y, Fu YX, Peng H. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Sci Immunol. 2022 Jan 7;7(67):eabi6899.

3. Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, Hsu E, Han C, Qiao J, Fu YX. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells. Nat Biomed Eng. 2021 Nov;5(11):1261-1273.

4. Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu EJ, Zhu J, Zhou J, Fu YX. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat Commun. 2021 Oct 7;12(1):5866.

5. Guo J, Liang Y, Xue D, Shen J, Cai Y, Zhu J, Fu YX, Peng H. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021 Nov;31(11):1190-1198.

6. Zhang A, Ren Z, Tseng KF, Liu X, Li H, Lu C, Cai Y, Minna JD, Fu YX. Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Sci Transl Med. 2021 Aug 4;13(605):eabg8693.

7. Hsu EJ, Cao X, Moon B, Bae J, Sun Z, Liu Z, Fu YX. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021 May 13;12(1):2768.

8. Han C, Godfrey V, Liu Z, Han Y, Liu L, Peng H, Weichselbaum RR, Zaki H, Fu YX. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Sci Immunol. 2021 May 7;6(59):eabc6998.

9. Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, Zhang Y, Ortega J, Zhang J, Siteni S, Chen M, Gu L, Shay JW, Davis AJ, Chen ZJ, Fu YX, Li GM. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer Cell. 2021 Jan 11;39(1):109-121.

10. Lu C, Guan J, Lu S, Jin Q, Rousseau B, Lu T, Stephens D, Zhang H, Zhu J, Yang M, Ren Z, Liang Y, Liu Z, Han C, Liu L, Cao X, Zhang A, Qiao J, Batten K, Chen M, Castrillon DH, Wang T, Li B, Diaz LA Jr, Li GM, Fu YX. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell. 2021 Jan 11;39(1):96-108.